Speakers

Biography

Brandon Lucke-Wold was born and raised in Colorado Springs, CO. He graduated magna cum laude with a BS in Neuroscience and distinction in honors from Baylor University. He completed his MD/PhD, Master’s in Clinical and Translational Research, and the Global Health Track at West Virginia University School of Medicine. His research focus was on traumatic brain injury, neurosurgical simulation, and stroke. At West Virginia University, he also served as a health coach for the Diabetes Prevention and Management program in Morgantown and Charleston, WV, significantly improving participants' health outcomes. In addition to his research and public health projects, he co-founded the biotechnology company SwiftScience and the pharmaceutical company ProPhos Neuroscience and was a science advocate on Capitol Hill through the Washington Fellow’s program.  
He has also been president of the WVU chapters of the American Association of Pharmaceutical Scientists, the Neurosurgery Interest Group, and the Erlenmeyer Initiative Entrepreneur group. In addition, he has served as vice president for the graduate student neuroscience interest group, Nu Rho Psi Honor Society, and medical students for global health. He was an active member of the Gold Humanism Honor Society and Alpha Omega Alpha Honor Society. He is currently Vice President of the UF House Staff Council, Chair of the Quality Improvement Committee, on the Board of Directors for the Alachua County Medical Society, and an active member of the Institutional Review Committee and Accreditation Requirements Review Committee. He is married to Noelle Lucke-Wold and has two children.  They enjoy running with their dogs, rock climbing, and traveling as a family.  Brandon frequently runs half marathons and 10ks with his wife in his spare time. Brandon also enjoys reading, playing piano, discussing philosophy, and playing chess. He is currently a Pgy6 neurosurgery resident at the University of Florida pursuing endovascular enfolded training. He was awarded the Dempsey Cerebrovascular Research Fellowship, SNS Fellowship, Van Wagenen Fellowship, R25 Grant, and SNIS Fellowship. 

Abstract

Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) remains a significant cause of morbidity and mortality. Post-hemorrhage cerebral vasospasm (PHCV) occurs through a complex pathophysiology, and numerous pharmacologic agents, including vasodilators, anti-inflammatories, and fibrinolytic, as well as endovascular techniques have been used to prevent and/or treat PHCV. Nimodipine remains the only agent with level 1 evidence, but other vasodilators have demonstrated promising results. Endovascular therapy likely has a role in treating severe/refractory PHCV, but randomized trials are needed to establish stronger evidence for this therapy. Numerous preclinical investigations highlight novel targets related to the immune response that could prove effective at improving outcomes in clinical trials.

Further investigation of the glymphatic system and its role in PHCV pathogenesis could result in novel pharmacologic targets. Future trials of these therapies and combinations of existing therapies are needed, and functional outcomes should be included as an endpoint. Further exploration of the neuroinflammatory reaction following aSAH will continue to identify targetable molecules involved in PHCV pathogenesis.